BFAM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now for an impatient entry: price is in a confirmed short-term downtrend (SMA_200 > SMA_20 > SMA_5) with MACD momentum still deteriorating, so downside follow-through risk remains high despite being oversold.", "RSI (6) at 19.55 suggests a bounce is possible, but without a proprietary buy signal and with earnings imminent (2026-02-16 after hours), the risk/reward is not attractive for an immediate buy.", "Intellectia Proprietary Trading Signals\n- AI Stock Picker: no signal on given stock today.\n- SwingMax: No signal on given stock recently."]
["Trend: Bearish structure (SMA_200 > SMA_20 > SMA_5) indicates persistent selling pressure.", "Momentum: MACD histogram -0.484 and negatively expanding = bearish momentum strengthening, not yet stabilizing.", "Mean-reversion setup: RSI_6 = 19.55 (oversold) increases probability of a short bounce, but oversold can persist in downtrends.", "Key levels: Pre-market ~86.83 is below S1 (88.447) and sitting near S2 (86.486); a break below S2 would be technically damaging. Pivot resistance overhead at 91.622 (then 94.796).", "Pattern/returns model: Similar-pattern stats imply ~+0.07% next day, +1.52% next week, -3.66% next month\u2014near-term bounce potential but unfavorable 1-month expectancy."]
can trigger short-covering/mean-reversion rallies."]
can imply complacency/low hedging, which can exacerbate downside if earnings disappoint."]
["Latest quarter provided: 2025/Q3.", "Revenue: $802.8M, +11.64% YoY (solid top-line growth).", "Net income: $78.6M, +43.07% YoY (profit growth outpacing revenue).", "EPS: $1.37, +45.74% YoY (strong earnings leverage).", "Gross margin: 26.85%, +7.92% YoY (margin expansion supports quality of growth)."]
["Recent changes trend: price targets have been cut and ratings remain cautious.", "2026-01-21 UBS: Neutral; PT cut to $107 from $120 (model reset ahead of Q4).", "2025-12-17 Morgan Stanley: Underweight; PT cut to $93 from $99 (more cautious stance).", "Wall Street pros: strong recent fundamental growth and potential upside if Q4/guidance re-accelerates; still meaningful upside to UBS PT vs current price.", "Wall Street cons: cautious/negative positioning from at least one major bank (Underweight) and multiple PT cuts suggest limited conviction until earnings/guidance clarify."]
